Major depressive disorder (MDD), a destabilizing psychiatric condition affecting an estimated 16.2% of adults worldwide, is characterized by persistent low mood, loss of interest in activities, and fatigue ([Kessler et al., 2003][1]). Current treatments largely target monoaminergic neurotransmitter